We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Research Partners Seek Antibodies for Cancer Therapy

By Biotechdaily staff writers
Posted on 25 Dec 2007
The discovery, development, and commercialization of novel therapeutic antibodies for the treatment of cancer are the objectives of new strategic research collaboration.

Oxford Genome Sciences (Oxford, UK) and Amgen (Thousand Oaks, CA, USA) plan to generate fully human antibodies using Amgen's proprietary XenoMouse technology. More...
These antibodies will be raised against the novel druggable targets that Oxford Genome Sciences has identified through its Oxford Genome Anatomy Project (OGAP) database.

OGAP maintains a database comprising what has been described as the world's largest proprietary collection of proteins. It integrates genomic, proteomics, and clinical information derived from blood and tissue studies for a large number of diseases from 50 different human tissues and representing 60 diseases. It contains over one million peptide sequences, mapped to approximately 15,000 genes, and over eight million SNPs and haplotypes. The OGAP oncology section contains proteomic data on 5,000 cancer membrane proteins combined with their genomic and clinical information derived from human blood and cancer tissue studies.

Dr Christian Rohlff, CEO of Oxford Genome Sciences said, "I am very happy to be collaborating with Amgen in our effort to discover and develop novel fully human antibodies for the treatment of cancer. I am confident that by using our complementary expertise we will be able to develop a promising and valuable pipeline of antibodies.”

Dr. Dave Lacey, head of research at Amgen, said, "We are pleased to enter into this collaboration that takes advantage of Amgen's expertise in monoclonal antibody technology and the database that Oxford Genome Sciences has established.”


Related Links:
Oxford Genome Sciences
Amgen

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.